We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

63 hedge funds and large institutions have $21M invested in TCR2 Therapeutics Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 23 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more call options, than puts

Call options by funds: $545K | Put options by funds: $187K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

22% less funds holding

Funds holding: 81 → 63 (-18)

35% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 23

53% less capital invested

Capital invested by funds: $45M → $21M (-$24.1M)

78% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 23

Holders
63
Holders Change
-18
Holders Change %
-22.22%
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
15
Reduced
23
Closed
23
Calls
$545K
Puts
$187K
Net Calls
+$358K
Net Calls Change
-$354K

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$640K
2
Citigroup
Citigroup
New York
+$638K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$258K
4
BCM
Bridgeway Capital Management
Texas
+$67.4K
5
Citadel Advisors
Citadel Advisors
Florida
+$56.2K

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$3.42M
2
TCM
Tang Capital Management
California
-$1.35M
3
RG
Redmile Group
California
-$490K
4
ACH
ArrowMark Colorado Holdings
Colorado
-$467K
5
BlackRock
BlackRock
New York
-$317K
Name Holding Trade Value Shares
Change 		Change in
Stake
BAM
51
Belpointe Asset Management
Nevada
$2.14K +$2.89K +2,147 New
Osaic Holdings
52
Osaic Holdings
Arizona
$2K +$744 +552 +69%
HWM
53
HighMark Wealth Management
Minnesota
$839 – – –
US Bancorp
54
US Bancorp
Minnesota
$699 – – –
BNP Paribas Financial Markets
55
BNP Paribas Financial Markets
France
$684 +$735 +545 +389%
FDCDDQ
56
Federation des caisses Desjardins du Quebec
Quebec, Canada
$500 – – –
Dimensional Fund Advisors
57
Dimensional Fund Advisors
Texas
$209 -$159K -117,830 -36%
BHWM
58
Beaird Harris Wealth Management
Texas
$61 – – –
NA
59
NewEdge Advisors
Louisiana
$47 +$63 +47 New
SIC
60
Salem Investment Counselors
North Carolina
$35 – – –
IRC
61
Investors Research Corp
Georgia
$15 – – –
KPF
62
K2 Principal Fund
Ontario, Canada
– -$3.42M -1,899,824 Closed
ACH
63
ArrowMark Colorado Holdings
Colorado
– -$467K -259,672 Closed
D.E. Shaw & Co
64
D.E. Shaw & Co
New York
– -$280K -155,495 Closed
AA
65
AlphaCentric Advisors
Puerto Rico
– -$272K -151,000 Closed
Jacobs Levy Equity Management
66
Jacobs Levy Equity Management
New Jersey
– -$150K -83,360 Closed
UOC
67
UBS O'Connor
Illinois
– -$97K -54,035 Closed
MAM
68
Marquette Asset Management
Minnesota
– -$72K -40,163 Closed
CSS
69
Cubist Systematic Strategies
Connecticut
– -$68K -38,005 Closed
JMPWA
70
JP Morgan Private Wealth Advisors
California
– -$46K -25,616 Closed
PP
71
PDT Partners
New York
– -$45K -25,225 Closed
Qube Research & Technologies (QRT)
72
Qube Research & Technologies (QRT)
United Kingdom
– -$42K -23,431 Closed
Ohio Public Employees Retirement System (OPERS)
73
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$34K -18,863 Closed
LPL Financial
74
LPL Financial
California
– -$33K -18,485 Closed
PCM
75
Prelude Capital Management
New York
– -$30K -16,715 Closed
1 2
3
4

TCRR Hedge Fund Activity: Q4 2022 in Review

63 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q4 2022, worth a combined $21M — down 53% from $45M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of TCRR and 5 opened new positions — a net loss of 18 holders — while 23 trimmed existing stakes and 15 added.

The largest buyer was Newtyn Management, adding an estimated $640K. The largest seller was K2 Principal Fund, exiting entirely with an estimated $3.42M sold.

  • 63 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q4 2022, down from 81 in Q3 2022.
  • Funds reported $21M of TCR2 Therapeutics Inc. Common Stock stock for Q4 2022, down 53% quarter-over-quarter.
  • 5 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q4 2022 and 23 closed out, a net change of -18 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q4 2022 was Newtyn Management, an estimated $640K added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q4 2022 was K2 Principal Fund, an estimated $3.42M sold.

Based on aggregated 13F filings for Q4 2022.